A study to compare effectiveness and safety of R-TPR-022/ Xolair® in Patients with asthma
- Conditions
- Health Condition 1: null- Patients withmoderate to severe persistent asthma
- Registration Number
- CTRI/2017/10/010093
- Lead Sponsor
- Reliance Life sciences Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 105
Males and females patients of >=18-65 years of age, inclusive.
- Patient with the diagnosis of moderate to severe persistent asthma >1 year duration
- Able to understand the study procedures, the risks involved, willing to provide written Informed Consent,
and able to adhere to study schedules and requirements.
- Subjects must have the ability to understand and comply with instructions and be able to complete
study-related forms and questionnaires.
- Men and women of childbearing potential must be using adequate birth control measures, as discussed with the study doctor and should agree to continue such precautions for 6 months after receiving the last
injection of study medication
- Menopausal females must have experienced their last period more than 12 months prior to study entry to be classified as not of childbearing potential.
- Any Clinically significant abnormal laboratory investigations or physical examination findings which
may pose risk to the patients as assessed by investigator at screening visit.
- Prior Hospitalisation or an emergency visit for asthma within the 4 weeks before the screening Visit.
- Patient with history of near fatal or life-threatening (including intubation) asthma within the past year
prior to screening visit.
- Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic
composition to Omalizumab or its any excipients. History of illicit drug use within one year prior to
randomization.
- Prior use of Omalizumab
- Known history of systemic (injectable or oral) corticosteroid medication use within 1 month of the
Screening Visit.
- Significant, non-reversible, active pulmonary disease.
- Current smoker or smoking history within 12 months prior to the Screening Visit.
- Myocardial infarction within 6 months of study enrollment; History of stroke within 6 months of study enrollment; Unstable symptomatic arrhythmia requiring medication; Clinically significant peripheral vascular disease; Uncontrolled diabetes; Serious active or uncontrolled infection
- History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an
investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.
- Inability to comply with study and/or follow-up procedures.
- Subjects with HIV, HBsAg, HCV test positive.
- History or presence of any form of cancer within the 10 years prior to randomization.
- Current signs or symptoms of significant, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral disease that renders the subject incapable of participating in the study
- History or presence of any medical or psychiatric condition or disease, or laboratory abnormality or any other condition that, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation and may prevent the subject from completing the study.
- Participation in any clinical study of an investigational product within the previous 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method